ASH 2023 | Blast enumeration & myelodysplasia-related gene mutations in NMP1-mutated myeloid malignancies
Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, speaks on a study analyzing the prognostic impact of blast enumeration and co-occurring myelodysplasia-related gene mutations in patients with NPM1-mutated myeloid neoplasms (MN). Despite updated guidelines defining acute myeloid leukemia (AML) in patients with greater than 10% blasts, the study found no significant difference in the molecular landscape or leukemia-free survival (LFS) between patients with greater than 10% blasts and less than 10% blasts. Patients without co-occurring myelodysplasia mutations demonstrated a significant survival advantage compared to those with such mutations. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Rigel, AbbVie, Servier, COTA Healthcare.
